IMMX

Immix Biopharma Announces Accelerated Nexicart-2 Clinical Trial Progress in Relapsed/Refractory Al Amyloidosis

时间：2025-07-07 21:35:00 市场： 美股 综合

关联： IMMX

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Nxc-201, Sterically-Optimized CAR-T for Relapsed/Refractory Al Amyloidosis

时间：2025-02-10 22:35:10 市场： 美股 综合

关联： IMMX

Immix Biopharma Inc: Enrollment in Nexicart-2 Study Accelerating; Next Update Planned for H1 2025

时间：2025-02-10 22:35:10 市场： 美股 综合

关联： IMMX

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized CAR-T Nxc-201 in Relapsed/Refractory Light Chain (Al) Amyloidosis

时间：2024-12-19 22:35:00 市场： 美股 综合

关联： IMMX

Immix Biopharma Advances CAR-T Nxc-201 to Expansion Cohort Dose Level in U.S. Al Amyloidosis Trial Nexicart-2

时间：2024-10-02 21:32:04 市场： 美股 综合

关联： IMMX

Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

时间：2024-09-19 21:31:00 市场： 综合 美股

关联： IMMX